Cas:392244-44-9 4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide manufacturer & supplier

We serve Chemical Name:4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide CAS:392244-44-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide

Chemical Name:4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide
CAS.NO:392244-44-9
Synonyms:4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide
Molecular Formula:C7H10ClN3OS
Molecular Weight:219.69200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.38g/cm3
Index of Refraction:1.594
PSA:83.12000
Exact Mass:219.02300
LogP:1.87700

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide Use and application,4-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)butanamide technical grade,usp/ep/jp grade.


Related News: The US-based study is evaluating the effect of ensifentrine on key outcomes in patients hospitalised with COVID-19, including facilitation of recovery from the viral infection, clinical status improvement and reduction in supplemental oxygen use and progression to mechanical ventilation. N-(1-(4-cyanophenyl)ethyl)-2-methylbicyclo[2.2.1]heptane-2-carboxamide manufacturers GBS is a rare but potentially life-threatening disorder in which the body’s immune system attacks nerve cells. The condition has been associated with the use of other widely used vaccines, such as GlaxoSmithKline’s Shingrix. 4,4-diethoxy-but-3-en-2-one suppliers Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.” 5-hydroxy-5-vinyl-hept-6-enoic acid methylamide vendor & factory.